Novonesis (novozymes) BNVZMF
13F holders, Q4 2024 (December 31)1holders
0new positions
0sold out
$56.61avg. 13F price*
At the end of Q4 2024, 1 institutions reported holding Novonesis (novozymes) B (NVZMF) in their 13F filings, unchanged from Q3 2024. 0 opened new positions and 0 sold out. The largest holder was Boston Common Asset Management, LLC ($968K).
- Company
- Novonesis (novozymes) B
- Filed as
- NOVOZYMES A/S (Q4 2024)
- CUSIP
- K7317J133
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 2,724 shares sold, net −2,724 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Boston Common Asset Management, LLC | 0.03% | Reduce -13.7% | 17,101 | $968K |
"% of holder's portfolio" is NVZMF's weight in each manager's 13F, not the share of Novonesis (novozymes) B the manager owns.